The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety

References

• . ; Emerging Risk Factors CollaborationSarwar N, Gao P, Seshasai SR, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Boussageon R, Bejan—Angoulvant T, Saadatian—Elahi M, . Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191–1201
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. December 2008. Accessed October 12, 2011
   Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76(4):912–917
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929–2940
   PubMed Web of Science ®Google Scholar
• . Meier JJ, Nauck MA. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab. 2004;18(4):587–606
   PubMedGoogle Scholar
• . Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29(1):46–52
   PubMed Web of Science ®Google Scholar
• . Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011; 124( 1 suppl):S3–S18
   PubMed Web of Science ®Google Scholar
• . Nikolaidis LA, Mankad S, Sokos GG, . Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–965
   PubMed Web of Science ®Google Scholar
• . Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–699
   PubMed Web of Science ®Google Scholar
• . Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215
   PubMed Web of Science ®Google Scholar
• . Mistry GC, Maes AL, Lasseter KC, . Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5): 592–598
   PubMed Web of Science ®Google Scholar
• . Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195–201
   PubMed Web of Science ®Google Scholar
• . Sauvé M, Ban K, Momen MA, . Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010; 59(4):1063–1073
   PubMed Web of Science ®Google Scholar
• . van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077
   PubMed Web of Science ®Google Scholar
• . Fadini GP, Boscaro E, Albiero M, . The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33(7):1607–1609
   PubMed Web of Science ®Google Scholar
• . Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med. 2009;121(6):70–100
   PubMed Web of Science ®Google Scholar
• . Williams—Herman D, Engel SS, Round E, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7
   PubMed Web of Science ®Google Scholar
• . Frederich R, Alexander JH, Fiedorek FT, . A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros—Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485–494
   PubMed Web of Science ®Google Scholar
• . Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3
   PubMed Web of Science ®Google Scholar
• . White WB, Gorelick PB, Fleck P, Smith N, Wilson C, Pratley R. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials. Presented at: 70th Scientific Sessions of the American Diabetes Association; June 25–29, 2010; Orlando, FL
   Google Scholar
• . Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27( suppl 3):57–64
   PubMed Web of Science ®Google Scholar
• . Ye Y, Keyes KT, Zhang C, Perez—Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010; 298(5):H1454–H1465
   PubMedGoogle Scholar
• . Ta NN, Schuyler CA, Li Y, Lopes—Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011;58(2):157–166
   PubMed Web of Science ®Google Scholar
• . Shah Z, Kampfrath T, Deiuliis JA, . Long-term dipeptidylpeptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011; 124(21):2338–2349
   PubMed Web of Science ®Google Scholar
• . Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats [published online ahead of print January 2, 2012]. Int J Cardiol.
   Google Scholar
• . Chaykovska L, von Websky K, Rahnenführer J, . Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011;6(11):e27861
   PubMed Web of Science ®Google Scholar
• . www.ClinicalTrials.gov. Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE). NCT00968708. http://clinicaltrials.gov/ct2/show/NCT00968708. Accessed October 12, 2011
   Google Scholar
• . www.ClinicalTrials.gov. CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. NCT01243424. http://clinicaltrials.gov/ct2/show/NCT01243424. Accessed October 12, 2011
   Google Scholar
• . www.ClinicalTrials.gov. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). NCT01107886. http://clinicaltrials.gov/ct2/show/NCT01107886. Accessed October 12, 2011
   Google Scholar
• . www.ClinicalTrials.gov. Sitagliptin cardiovascular outcome study (0431-082 AM1) (TECOS). NCT00790205. http://clinicaltrials.gov/ct2/show/NCT00790205. Accessed October 12, 2011
   Google Scholar